Advertisement
Advertisement
U.S. Markets open in 7 hrs 37 mins
Advertisement
Advertisement
Advertisement
Advertisement

Royalty Pharma plc (RPRX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
37.500.00 (0.00%)
At close: 4:00PM EDT
Advertisement
Sign in to post a message.
  • R
    Robert
    I have tried to find a reason to like this stock enough to purchase shares. I’ve followed this company since before it’s IPO. I even sat on a little cash waiting to pull the trigger. I’ve finally came to the conclusion this stock is going nowhere fast. In theory, it’s a good company. In reality, it’s a horrible investment. Good luck longs.
  • P
    Paul
    Well well - what a surprise. Look what's on Harvard's list of top 10 stocks checking in at #2 behind Apple! It's Royalty Pharmaceutical. Here's the article:

    https://finance.yahoo.com/news/harvard-university-stock-portfolio-top-131810330.html
  • r
    robert
    seems like only scott understands finance and how this company uses their cash...as soon as covid cools dodn and 1 phase 3 trial is approved you will never see this level again...stay strong scott they dont understand the business model and how much cashflow they recieve. the ceo is a genius at what he does.
  • X
    X
    Just looked briefly at this company. Wow, does the CEO really make $55 million a year?
  • B
    Buylowsellhigh
    This RPRX is the FNV variant of the Pharmaceutical business and if asked to the equivalent of WPM, I think LGND will become the first to name.
  • M
    Moosehead
    I love this. Small rise over a week after
    August 11, 2021 Q2 2021 Earnings Release $1.08 Est. $0.64 to $0.72
    Sitting now at 15x earnings- nice comfy multiple in a crazy market.
    This is a great one for having time to build a nice position, letting it ride and in 5-10 years should be throwing off cash like crazy.
  • B
    Barney
    A ton of recent insider selling. BEWARE.
  • B
    Bill
    Cramer keeps pumping this stock and it keeps going down.
  • K
    Kenneth
    Bullish
  • S
    SM
    Why exactly has it moved up after taking on $2B in debt?
    Neutral
  • M
    Maury
    RPRX is a long term gem. I am increasing my position due to its low price.
    Bullish
  • j
    johnszn
    added more
  • S
    Shorty McShortBear
    I have narrowed my next Pure Earnings Short Sell play down to either RPRX or WIX. Right now I am definitely leaning in favor of RPRX, even though WIX is significantly more over-valued. One of the many wrinkles in the Pure Earnings Short Sell game is that you almost never can know when a company will deliver a big earnings surprise to the upside.

    But, because of the RPRX business model, we CAN reasonably assume that this past quarter was not super-duper chock full of unexpected profits. We have no recent FDA big drug approvals upon which RPRX can claim new and very large royalties. The company can tease the "likelihood" of such approvals coming up in the future, but of course there is absolutely no guarantee if, when, or how many, such approvals there might be.

    Do I wish RPRX was in the Green today, and was even more over-valued?? Of course. But it still looks like an extremely attractive Short Sell to hold through earnings release, especially if WIX stays in the Red for the next few hours, too.

    I will make a final decision between 3-4 PM ET, on which play to make.

    Good Luck Folks!
    Bearish
  • s
    simon
    $1.37 up after hour. Look like good news for report.
  • S
    Shorty McShortBear
    This baby is stuck in a very tight range. Got support at the $36.00 level, got no support above $36.25. Is she gonna stay like this all the way until 3:30 ET?? I don't think so. Either way she is below yesterday's close and range. Clearly weaker. The odds favor a slow breakdown to the $35.60 level, far more than a breakout to the $36.60 level. It's worth it for me to stay Short, got many thousands of shares so every penny of profit counts. Meanwhile EBAY is acting solidly Green and even trending up, so there is no reason for me to rush into that Pure Earnings Short Sell until later on today.
    Bearish
  • S
    Shorty McShortBear
    I am researching RPRX as a very attractive Pure Earnings Short Sell play for Tuesday of this week. Despite the large drop in share price in recent months, RPRX still looks very pricey and over-valued. I am analyzing both current/recent financials, and the validity of the business model they seem to be deploying, and to me this seems like a very poor business model that is essentially playing the lottery with very bad odds, in terms of them desperately hoping a bunch of their "royalty" drugs gain full FDA approval and become billion dollar sellers on the retail market. What I see is them throwing money at lots of "potentially" billion dollar drugs, but absent a high rate of actual breakthrough successes, the money they are throwing at the drugs is likely to surpass the money they will be able to generate via their "royalty" system.

    You see a consistent decline in EPS and a lot of very recent insider selling despite the depressed share price. High debt load, high P/E Ratio, and poor growth rate. A very new company on the public trading platform, that has not earned any respect from investors. If they deliver a poor ER Wednesday morning, I can easily see this one dropping 6-12% from the $37.00 level.

    Looks Bearish to me and an excellent risk/reward Pure Earnings Short Sell trade.
    Bearish
  • S
    Shorty McShortBear
    Earnings are out:

    Royalty Pharma Reports Second Quarter 2021 Results

    Net cash provided by operating activities (GAAP) was $532 million in the second quarter of 2021, an increase of 9%, compared to $489 million in the same period of 2020. The increase in the second quarter of 2021 resulted primarily from a decline in interest paid due to a change in the timing of interest payments from quarterly to semi-annually and higher cash collections from royalty assets. Payments for operating and professional costs in the second quarter of 2021 were slightly lower compared to the same period of 2020.

    Total royalty receipts were $588 million in the second quarter of 2021, a slight increase compared to $585 million in the same period of 2020. Growth in the second quarter of 2021 was largely attributable to the performance of the cystic fibrosis franchise, fixed payments from Biohaven on the Series A Preferred Shares and the addition of new royalties, partially offset by a decrease in royalty receipts from the HIV franchise due to loss of exclusivity for Truvada and Atripla as well as a lower percentage of combination sales attributable to emtricitabine in the United States. Furthermore, in the three months ended June 30, 2020, a distribution from Avillion was received for the discontinuation of a product in development, which created a higher base of comparison.

    Drivers of royalty receipts in the second quarter of 2021 are discussed below, based on commentary from the marketers of the products underlying the royalties in the preceding quarter (as royalty receipts generally lag product performance by one calendar quarter).
    Bearish
  • s
    scott
    More heavy volume block trades today...are these buys or sells?
  • Y
    Yee
    Hey did they forget the dividend they promised
  • C
    Cameron
    $RPRX got bought out by Allergan for far less than the substantial tax break it will receive from the culminated carryover loss value of a company that spent hundreds of millions of dollars over 30 years and returned nothing.
Advertisement
Advertisement